Method for detecting all Haemophilus influenzae
    22.
    发明公开
    Method for detecting all Haemophilus influenzae 审中-公开
    维也纳公民嗜血杆菌流感嗜血杆菌

    公开(公告)号:EP2657704A1

    公开(公告)日:2013-10-30

    申请号:EP13003285.7

    申请日:2010-01-05

    IPC分类号: G01N33/569 C07K16/10

    摘要: An immunological assay method for detection of all Haemophilus influenzae strains in respiratory tract infection, otitis media or sepsis in infants or children, said method comprising measuring the amount of the P6 antigen contained in a test sample from a patient and employing a polyclonal antibody which recognizes the P6 antigen of Haemophilus influenzae, wherein said method employs an ELISA system or an immunochromatography assay system.

    摘要翻译: 一种用于检测呼吸道感染,中耳炎或婴儿或儿童败血症的所有流感嗜血杆菌菌株的免疫测定方法,所述方法包括测量来自患者的测试样品中含有的P6抗原的量,并使用识别的多克隆抗体 流感嗜血杆菌的P6抗原,其中所述方法采用ELISA系统或免疫色谱测定系统。

    METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR TECHNICAL MANAGEMENT AND BIOCONTROL OF DISEASE IN ANIMAL PRODUCTION SYSTEMS
    26.
    发明公开
    METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR TECHNICAL MANAGEMENT AND BIOCONTROL OF DISEASE IN ANIMAL PRODUCTION SYSTEMS 审中-公开
    方法,系统和计算机程序产品,用于动物生产系统技术管理和生物防治疾病

    公开(公告)号:EP1358479A2

    公开(公告)日:2003-11-05

    申请号:EP01975178.3

    申请日:2001-09-25

    申请人: Acuabiotec LLC

    IPC分类号: G01N33/48

    摘要: A system, method and computer program product for controlling disease at an end user location, including (a) testing a range of candidates including at least one of: (i) Bacillus species, (i) Bacillus strains, (iii) species of beneficial bacteria (iv) strains of beneficial bacteria and (v) strains of beneficial bacterial viruses, against samples including at least one of pathogenic Vibrio, Gram negative pathogenic bacteria and Gram positive pathogenic bacteria taken from an end user location; (b) performing at least one of the following steps: (i) selecting one or more of the candidates that one of inhibit and attack at least one of the samples by direct inhibition of at least one of in situ antibiotic production, competitive exclusion, production of enzymes that degrade quorum sensing molecules, and (ii) testing a range of quorum sensing inhibitor compounds against the samples; and (c) performing the steps (a) and (b) for the end user location, including one of a country, major region and individual end user location, to target microbial technology to use in bio-control of disease specific to the end user location.